New combo therapy aims to shrink Hard-to-Treat tumors

NCT ID NCT07095868

Recruiting now Disease control Sponsor: Everest Medicines (Beijing) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 05, 2026 · Updated 19 times

Summary

This study tests a new drug called EVM14, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety and see if the treatment can control or shrink tumors. About 94 adults with certain types of cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, 410006, China
MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10022, United States

Contact Email: •••••@•••••
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
Nanjing Drum Tower Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210000, China
Shanghai Chest Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200030, China
The First Affiliated Hospital With Nanjing Medical University
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210029, China

Conditions

Explore the condition pages connected to this study.

SELECTED TYPES OF SOLID TUMOR SELECTED TYPES OF SOLID TUMOR